Inventor · disambiguated record
Courtney G. Havens
Also filed as: HAVENS COURTNEY G
6 granted patents·3 pending applications·32 citations·filing 2014–2024
80Inventor score
Files withCELGENE CORP9
Top patents by PatentIndex Score
9 records- 0196US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0295US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0389US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0486US11726080B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2021·Granted Aug 15, 2023·1 cites·21 claims
- 0582US10969381B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2019·Granted Apr 6, 2021·1 cites·16 claims
- 0682US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 0777US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 0867US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 0954US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Courtney G. Havens files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →